Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer

Figure 5 Recurrence and metastasis patterns based on perioperative carcinoembryonic antigen. A: Relative frequencies of recurrence or metastasis sites for patients in the training cohort based on preoperative carcinoembryonic antigen (pre-CEA); B: Relative frequencies of recurrence or metastasis sites for patients in the training cohort based on postoperative carcinoembryonic antigen (post-CEA); C: Annual recurrence or metastasis hazard curves for patients in the training cohort based on pre-CEA; D: Annual recurrence or metastasis hazard curves for patients in the training cohort based on post-CEA; E: Relative frequencies of recurrence or metastasis sites for patients in the validation cohort based on pre-CEA; F: Relative frequencies of recurrence or metastasis sites for patients in the validation cohort based on post-CEA; G: Annual recurrence or metastasis hazard rates for patients in the validation cohort based on pre-CEA; H: Annual recurrence or metastasis hazard rates for patients in the validation cohort based on post-CEA. pre-CEA: Preoperative carcinoembryonic antigen; post-CEA: Postoperative carcinoembryonic antigen.